ClinicalTrials.gg
Not yet recruitingNCT07745465MyBackExerciseUpdated Aug 4, 2026

Self-Selected Versus Physiotherapist-Prescribed Resistance Training Program In People With Chronic Low Back Pain

An interventional study of Control group and Experimental group in People With Chronic Low Back Pain, sponsored by University of Cadiz. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by University of Cadiz · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Chronic low back pain is a public health issue affecting over 20% of the Spanish population, causing disability, reduced quality of life, and work absenteeism. Over the past decades, the benefits of physical exercise for improving symptoms in patients with chronic low back pain have been studied. Exercise has also been shown to improve quality of life, general health, self-efficacy, and fear of pain, regardless of pathology. Research on the effect of physical exercise in chronic low back pain patients has shown promising results. Therefore, the therapeutic exercise program proposed in this study may help participants adopt healthy habits that positively impact their quality of life.

This will be a clinical trial in patients with chronic low back pain. The main purpose of the study is to evaluate the efficacy of a self-selected resistance training program versus physiotherapist-prescribed exercises in improving pain intensity and disability in adults with chronic low back pain. Secondary objectives include evaluating differences between the two groups after 12 weeks in treatment satisfaction, degree of compliance, kinesiophobia, self-efficacy, muscle endurance, and lumbar electromyographic activity.

If you agree to participate, a member of the research team experienced in exercise programs for chronic low back pain will instruct you on how to perform the program. The follow-up study will include 34 participants randomly assigned to two groups: one group performing self-selected resistance exercises, and one group performing physiotherapist-prescribed exercises. The study will last 12 weeks, assessing your condition at the start and end of the study. You will complete questionnaires on pain intensity (Numerical Pain Rating Scale, NPRS), disability (Oswestry Disability Index, ODI), treatment satisfaction (CRES-4), adherence to treatment, kinesiophobia (TSK-11), self-efficacy (Pain Self-Efficacy Questionnaire, PSEQ), muscle endurance (Biering-Sørensen test), and surface electromyographic activity of the erector spinae (longissimus) muscle (sEMG-ESL) using the mDurance® device.

POTENTIAL BENEFITS AND RISKS OF PARTICIPATION Expected direct benefits of participation may include improvements in pain intensity, disability, treatment satisfaction, adherence to therapeutic exercise, kinesiophobia, self-efficacy, muscle endurance, and electromyographic activity.

However, it is possible that you may not experience any personal benefit. The information obtained will contribute to scientific knowledge about CLBP and may help others in the future.

ALTERNATIVE TREATMENTS Chronic low back pain is a pathological entity with extensive study, which can present different conservative therapeutic options, such as psychological therapy, regular physical exercise and the adoption of healthy habits.

COMPENSATION Participation in this study will not incur any costs for you. OTHER RELEVANT INFORMATION Any new information discovered during your participation that may affect your willingness to participate in the study will be communicated to you by your doctor as soon as possible.

If you decide to withdraw your consent to participate in this study, no new data will be added to the database, and if samples have already been collected, you may request the destruction of all previously obtained, identifiable samples to avoid further analysis.

You should also be aware that you may be excluded from the study if the sponsor or researchers deem it necessary, either for safety reasons or because they believe you are not complying with the established procedures.

In either case, you will receive a clear explanation of the reason for your withdrawal from the study. The sponsor may suspend the study for any of the reasons stipulated in current legislation.

By signing the attached consent form, you agree to comply with the study procedures explained to you. When your participation is over, you will receive the best available treatment that your doctor considers most appropriate for your condition.

02

Conditions studied

  • People With Chronic Low Back Pain

Browse trials for

Keywords

  • Chronic Low Back Pain
  • Exercise Therapy
  • Resistance Training
  • Self-selected exercise
  • Physiotherapy
03

In context

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

This study's planned enrollment of 34 is below the median of 60 across 2,369 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

University of Cadiz is the lead sponsor of 55 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

a) Male and female participants aged 18-65 years b) Low back pain, with or without referred pain to the lower limb, persisting for ≥12 weeks c) Not currently engaged in a regular structured exercise programme d) Sufficient cognitive and communication abilities to complete the assessment scales and participate in the study intervention Exclusion Criteria

  1. Lumbar radiculopathy or radicular pain syndrome, defined by clinical signs of nerve root involvement (e.g., dermatomal pain, neurological deficits, or positive neurodynamic tests)
  2. Serious spinal or non-spinal pathology explaining low back pain, identified through clinical assessment (e.g., , vertebral fracture, spinal infection, cauda equina syndrome, inflammatory spinal disease, vascular, visceral or other serious causes).
  3. Medical to exercise, as determined by the treating physician The presence of lumbar degenerative imaging findings (e.g., degenerative disc disease, lumbar spondylosis, facet joint osteoarthritis, or Modic changes) will not constitute an exclusion criterion, provided that the clinical presentation is consistent with chronic low back pain.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Arm experimental

    Behavioral: Experimental group

  • Active comparator
    Arm control

    Behavioral: Control group

Interventions

  • BehavioralControl group

    The control group will carry out a physiotherapist-prescribed RT programme. Participants in this group will not be able to choose their exercises and will perform six exercises: push-ups, row, squat, deadlift, abdominal crunch and back extension.

  • BehavioralExperimental group

    The experimental group will follow a programme with different RT options. This proposal will be displayed on a board with detailed images of the exercises in the treatment centre. Each patient will individually choose six exercises daily; two for each body part (upper limb; lower limb; trunk). Each patient's individual choice of exercises will be recorded using checklists. Under no circumstances will the physiotherapist guidance take precedence; the clinician will refrain from expressing their preferences and beliefs regarding the selected-exercise. The patient will have the option to repeat or vary the exercises throughout the training programme, if they so decide. For both groups, the treatment materials will include variable-resistance elastic bands, adjustable dumbbells, chairs, and a roman chair. Therapeutic supervision will be provided face-to-face for all study participants by three experimented physiotherapists from the research group.

06

What researchers measure

Primary outcomes

  1. Pain-related distribution and intensity

    Pain distribution will be evaluated using a 45-region body map to identify painful body areas. Pain intensity will be measured separately for low back pain and leg pain using the Numerical Pain Rating Scale (NPRS), a continuous measure ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Disability

    Disability will be measured as a discrete quantitative variable using the Oswestry Disability Index (ODI), with a total score ranging from 0 to 50 points, reflecting the degree of functional limitation associated with CLBP.

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Treatment satisfaction

    Treatment satisfaction will be evaluated as an ordinal quantitative variable using the Treatment Satisfaction Scale (CRES-4), with total scores ranging from 4 to 20 points, where higher scores indicate greater satisfaction with the received treatment.

    Time frame: From T1 (4 weeks) to the end of treatment at 12 weeks

  2. Degree of compliance

    Degree of compliance with treatment will be assessed as an ordinal quantitative variable based on the percentage of completed sessions out of the total 24 scheduled sessions.

    Time frame: From T1 (4 weeks) to the end of treatment at 12 weeks

  3. Kinesiophobia

    Kinesiophobia will be measured as a continuous quantitative variable using the Tampa Scale for Kinesiophobia (TSK-11), with scores ranging from 11 to 44 points, where higher scores reflect greater fear of movement.

    Time frame: From enrollment to the end of treatment at 12 weeks

  4. Self-efficacy

    Self-efficacy will be assessed as an ordinal quantitative variable using the Pain Self-Efficacy Questionnaire (PSEQ), with scores ranging from 0 to 60 points, indicating the individual's confidence in performing daily activities despite pain.

    Time frame: From enrollment to the end of treatment at 12 weeks

  5. Muscle endurance

    Muscle endurance will be evaluated as a continuous quantitative variable using the Biering-Sørensen test, with performance time ranging from 0 to 240 seconds.

    Time frame: From enrollment to the end of treatment at 12 weeks

  6. Surface electromyographic activity of the erector spinae (longissimus) muscle (sEMG-ESL)

    The activity of the erector spinae (longissimus) muscle will be assessed as a continuous quantitative variable using surface electromyography, expressed in microvolts (μV), and quantified through the root mean square (RMS) using the mDurance® device.

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — To ensure the privacy and confidentiality of participants, all clinical data collected in the study will be anonymized prior to analysis. Names, identification numbers, and specific dates will be removed, and any indirect identifiers that could allow subject identification will be grouped and coded. The anonymization process will be conducted in accordance with current ethical and regulatory standards, ensuring that the data remain valid for statistical analysis without compromising individual privacy. All physical documents will be stored in locked filing cabinets within a secure area with restricted access. Electronic data will be entered into a secure, password-protected database specifically designed for the study. Access to the data will be limited to research team members listed in the study protocol. Data supporting the findings of this study will not be publicly available due to sensitivity but may be obtained from the corresponding author upon justified request. All data will

Supporting information: Study protocol, Informed consent form

Time frame: 01-09-2026 // 01-09-2027

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 6 months is below that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 4, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Dec 2027
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07745465
Lead sponsor
University of Cadiz
Collaborators
Instituto de Investigacion Sanitaria La Fe
Responsible party
Luis Gonzalez Gomez (MSc., University of Cadiz) — Principal investigator
First posted
Aug 4, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 4, 2026

Study contacts

Luis González Gómez, PT, MSc
Contact
luis.gonzalezgomez@alum.uca.es
637958168 ext. +34
Francisco José García Bustos, PT
Contact
garcia_frabus@gva.es
654623204 ext. +34
José A. Moral Muñoz, PT, PhD
study director · University of Cadiz (Spain)
Álvaro José Rodríguez Domínguez,, PT, PhD
study director · Centro Universitario San Isidoro, affiliated with Pablo de Olavide University (Spain)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion